Evidence map›Paper›PMID 27663671›Full record

ArticleVaccine2016

Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.

Peter Pushko, Xiangjie Sun, Irina Tretyakova, Rachmat Hidajat, Joanna A Pulit-Penaloza, Jessica A Belser, Taronna R Maines, Terrence M Tumpey

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Peter PushkoMedigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA. Electronic address: ppushko@medigen-usa.com.
Xiangjie SunInfluenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Irina TretyakovaMedigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA.
Rachmat HidajatMedigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA.
Joanna A Pulit-PenalozaInfluenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Jessica A BelserInfluenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Taronna R MainesInfluenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Terrence M TumpeyInfluenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Centers for Disease Control and Prevention · USMedigen (United States) · US

Funding

Broad-Range VLP Vaccine Against H5N1 InfluenzaR01AI111532 · NIAID · MEDIGEN, INC. · PI PUSHKO, PETER M. · 2014 to 2017
$1.5M
NIAID NIH HHS R01 AI111532
6 · The paper itself

Abstract

Avian-origin influenza represents a global public health concern. In 2013, the H10N8 virus caused documented human infections for the first time. Currently, there is no approved vaccine against H10 influenza. Recombinant virus-like particles (VLPs) represent a promising vaccine approach. In this study, we evaluated H10 VLPs containing hemagglutinin from H10N8 virus as an experimental vaccine in a ferret challenge model. In addition, we evaluated quadri-subtype VLPs co-localizing H5, H7, H9 and H10 subtypes. Both vaccines elicited serum antibody that reacted with the homologous H10 derived from H10N8 virus and cross-reacted with the heterologous H10N1 virus. Quadri-subtype vaccine also elicited serum antibody to the homologous H5, H7, and H9 antigens and cross-reacted with multiple clades of H5N1 virus. After heterologous challenge with the H10N1 virus, all vaccinated ferrets showed significantly reduced titers of replicating virus in the respiratory tract indicating protective effect of vaccination with either H10 VLPs or with quadri-subtype VLPs.

Indexed as

AnimalsAntibodies, ViralCross ReactionsFerretsHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A Virus, H10N8 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza, HumanInfluenza VaccinesOrthomyxoviridae InfectionsVaccines, Virus-Like ParticleVirus ReplicationAntibodies, Viralhemagglutinin, avian influenza A virusHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesVaccines, Virus-Like ParticleBaculovirusH10N8InfluenzaRecombinant vaccineVirus-like particlesVLP

Identifiers

PMID27663671
PMCPMC5063076
OpenAlexW2522189801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.